Turn Therapeutics Inc. (TTRX) News
Follow Turn Therapeutics Inc. (TTRX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Turn Therapeutics Initiated at Buy by LUCID CAPITAL MARKETS
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 11:49 AM UTC
L
Turn Therapeutics to present at Stifel forum
The company said it will present updated atopic dermatitis data and a pruritus-focused Stage 2 enrichment strategy at Stifel 2026.
EQUITY | Sep 10, 2026, 12:14 PM UTC
L
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and Ste
EQUITY | Sep 10, 2026, 12:00 PM UTC
L
Turn Therapeutics appoints Robert R. Redfield as chief scientific officer
Turn Therapeutics appointed Robert R. Redfield as chief scientific officer to advance scientific and clinical strategy for GX-03.
REGULATION | Sep 09, 2026, 12:13 PM UTC
L
Turn Therapeutics appoints Robert R. Redfield as Chief Scientific Officer
Turn Therapeutics Inc. announced the appointment of Robert R. Redfield, M.D., as Chief Scientific Officer. The company is a clinical-stage biotech focused on targeted, non-systemic therapies for inflammatory and infectio
EQUITY | Sep 09, 2026, 12:00 PM UTC